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doi:10.1016/j.jhep.2009.04.006The association of HBV core promoter double mutations (A1762T
and G1764A) with viral load diﬀers between HBeAg positive
and anti-HBe positive individuals: A longitudinal analysis – ReplyTo the Editor:
Pan et al. [1] have expressed two concerns regarding
our study. First, although no study subjects received
antiviral therapy during the period of follow-up, some
individuals may have been treated prior to the study.
The members of the Long An cohort are low-income
agricultural workers unlikely to be able to aﬀord antivi-
ral drugs, and none reported their use when questioned
speciﬁcally at recruitment. Even if a few individuals had
received therapy previously, their viral loads should
have rebounded after the end of treatment and the lon-
gitudinal analysis carried out ensured that our results
would not have been inﬂuenced. Furthermore, the
diﬀerential eﬀects of BCP mutations on viral load in
HBeAg-positive and in HBeAg-negative patients have
been reported by other investigators [2]. The strength
of our study lies in the longitudinal analysis.
Their second point is that other factors, such as age,
sex and viral genotype, may have inﬂuenced the viral
loads. As stated in the methods Section 2.7.1 ‘Cross-sec-
tional analysis’, multiple linear regression analysis was
used to assess whether any diﬀerences detected remained
signiﬁcant after adjusting for HBeAg status and those
speciﬁc factors [3]. That was the case, although, for rea-
sons of brevity, those analyses were not detailed in thepaper. We do not consider that either of these issues
compromises our ﬁndings.
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doi:10.1016/j.jhep.2009.04.005The retroviral myth of primary biliary cirrhosis:
Is this (ﬁnally) the end of the story?
To the Editor:
The retroviral story of primary biliary cirrhosis
(PBC) has been enriched by a new episode in the
March issue of this Journal. In their article, Johal
and colleagues report their study of a large number
of liver samples taken from patients aﬀected by
